Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.68 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.68 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.68 |
| ▸ | BRD4 | O60885 | 2/20 | 0.62 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915299 | 0.95 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL4593480 | 0.95 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL4915342 | 0.95 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL4915292 | 0.95 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL4915442 | 0.89 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL4920875 | 0.87 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL4915290 | 0.86 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| SCHEMBL7722180 | 0.81 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11BRD4 | |
| Vk-19911 SCHEMBL140202 | 0.81 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4915591 | 0.81 | MAPK14 (1.00) | MAPK14BRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0900083-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-08-20 | — | — | EP | claimed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | PROTTER ANDREW A | 2008-02-14 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1676574-A2 | Methods for promoting survival of transplanted tissues and cells | Johnson & Johnson Vision Care, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | SCIOS INC. | 2006-01-26 | — | — | US | disclosed |
| US-20050129729-A1 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. | 2005-06-16 | — | — | US | disclosed |
| US-20040171659-A1 | Methods for treating diabetes | SCIOS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040162289-A1 | Methods of promoting osteogenesis | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2004-08-19 | — | — | US | disclosed |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | SCIOS, INC. | 2004-06-24 | — | — | US | disclosed |
| EP-0900083-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6387898-B1 | USING IMIDAZOLE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-6096739-A | Treatment for CNS injuries | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | MAPKAPK5, MAPK1, MAPKAPK2 | MAPK14 36/4885MAPK13 34/4885MAPK12 27/4885 |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | MAPK14 23/4885MAPK13 15/4885MAPK12 30/4885 |
| US-20040162289-A1 | Methods of promoting osteogenesis | MAPK1, BMP2, MAPK3 | MAPK14 23/4885MAPK13 15/4885MAPK12 30/4885 |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | OPRK1, OPRL1, MAPK3 | MAPK14 36/4885MAPK13 39/4885MAPK12 28/4885 |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | OPRK1, OPRL1, MAPK3 | MAPK14 36/4885MAPK13 39/4885MAPK12 28/4885 |
| US-20040171659-A1 | Methods for treating diabetes | SLC5A2, MAPK4, MAPK3 | MAPK14 53/4885MAPK13 46/4885MAPK12 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.